Medicare Officially Limits Aduhelm Coverage to Clinical Patients
Over the past few months, Medicare officials have been overflowing with enthusiasm for how coverage of the controversial new Alzheimer’s drug Aduhelm will be handled. Advocacy groups for patients said the federal insurance program for people 65 and older should pay for a drug approved by the Food and Drug Administration. Many Alzheimer’s doctors and …
Continue reading “Medicare Officially Limits Aduhelm Coverage to Clinical Patients”